Avelumab

1 Drug classified under this active ingredient

Human Monoclonal Antibody. Avelumab 20 mg / ml.
VIAL (conc. For sol. For infus.) 1 x 10 ml. MCC or UC: 800 mg or 10 mg/kg body weight, accord. to treat. Physician's discretion, admin. as a IV infus. over 60 min. every 2 wks. until dis. progress. or unacceptab. toxicity.
RCC: 800 mg or 10 mg/kg body weight, accord. to treat. Physician's discretion, admin. as a IV infus. over 60 min. every 2 wks. in comb. with axitinib 5 mg oral. taken twice daily until dis. progress. or unacceptab. toxicity. see lit.
Tmt. of adlt.pts. with metastat. Merkel cell carcinoma (MCC).
Maint. tmt. of pts. with local. adv. or metastat. urothelial carcinoma (UC) that has not progress. with first-line platinum-containing chemother.
Tmt. of pts. with local. adv. or metastat. urothelial carcinoma (UC) who:
- Have dis. progress. during or follow. platinum-containing chemother.
- Have dis.  progress. within 12 months of neoadjuvant or adjuvant tmt.
  with platinum-containing chemother.
First-line tmt. of pts. with adv. renal cell carcinoma (RCC) in comb. with axitinib.
C/I: Hypersens.